| Shuxian Qu,Zhaozhe Liu,Zhendong Zheng,Zhenyu Ding,Tao Han,Fang Guo,Jianing Qiu,Xiaodong Xie,Dongchu Ma. The influence of autologous cytokine-induced killer cell treatment on the objective efficacy and safety of gefitinib in advanced non-small cell lung cancer. Oncol Transl Med, 2015, 1: 69-72. |
| 自体CIK对吉非替尼治疗晚期非小细胞肺癌客观疗效及安全性的影响 |
| The influence of autologous cytokine-induced killer cell treatment on the objective efficacy and safety of gefitinib in advanced non-small cell lung cancer |
| Received:January 12, 2015 Revised:April 07, 2015 |
| DOI：10.1007/s10330-015-0057-0 |
| 中文关键词: 非小细胞肺癌；吉非替尼；CIK治疗 |
| 英文关键词: non-small cell lung cancer (NSCLC); gefitinib; cytokine-induced killer (CIK) cell |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Shuxian Qu | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | qushuxian2010@163.com | | Zhaozhe Liu | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | doctor_xxd@163.com | | Zhendong Zheng | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | doctor_xxd@163.com | | Zhenyu Ding | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | doctor_xxd@163.com | | Tao Han | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | doctor_xxd@163.com | | Fang Guo | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | doctor_xxd@163.com | | Jianing Qiu | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | doctor_xxd@163.com | | Xiaodong Xie | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | doctor_xxd@163.com | | Dongchu Ma* | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110840, China | mdc580819@sina.com |
|
| Hits: 8609 |
| Download times: 10113 |
| 中文摘要: |
| 目的 观察自体CIK细胞联合盐酸吉非替尼（Gefitinib）治疗晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）的疗效及安全性。方法 将应用盐酸吉非替尼二线治疗的66例NSCLC患者随机分成2组（分组前签署知情同意书），对照组给予盐酸吉非替尼治疗，观察组给予自体CIK细胞联合吉非替尼治疗，评价两组患者客观疗及毒副反应。 结果 观察组患者客观总控制率略高于对照组，但无统计学差异（P>0.05）。观察组患者的腹泻、乏力、口腔溃疡、食欲不振及骨髓抑制的发生率均显著低于对照组(P<0.05)，但在皮疹、肝肾毒性等方面无差异（P>0.05）。结论自体CIK细胞联合盐酸吉非替尼二线对晚期非小细胞肺癌有效，且可显著减轻毒副反应，提高安全性。 |
| 英文摘要: |
| Objective: The aim of the study was to observe the influence of autologous cytokine-induced killer cell (CIK) treatment on the objective efficacy and safety of gefitinib in advanced non-small cell lung cancer (NSCLC).
Methods: Sixty-six patients with NSCLC received gefitinib as second-line treatment. They were randomly divided into 2 groups, and informed consent forms were signed before grouping. Gefitinib was administrated to the control group, and autologous CIK treatment was added to the observation group. The objective treatment and adverse reactions were evaluated in both groups.
Results: The objective response rate (ORR) and the disease control rate (DCR) of the observation group were slightly higher than those of the control group, although no statistical differences were found between the 2 groups (P > 0.05). The incidences of diarrhea, fatigue, anorexia, oral ulcers, and myelosuppression in the observation group were much lower than those in the control group (P < 0.05). However, there were no statistical differences between the incidences of skin rash, and liver and kidney toxicities (P > 0.05).
Conclusion: Autologous CIK in combination with gefitinib is effective as second-line treatment for advanced NSCLC, and can significantly reduce adverse reactions and improve the objective efficacy. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|